Tusamitam Ravtansine (IBI126)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tusamitam Ravtansine (IBI126), covering 2024-08-20 to 2024-08-20. Get the full timeline:
Most recent: Clinical Trial Update: The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) [Phase 2]